Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

NCT07359040 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Neoadjuvant Therapy
PD-1 Inhibitors
Immunotherapy

Interventions

DRUG: Ivonescimab
DRUG: PD-1 Inhibitors

Sponsor

Peking University People's Hospital